AnalystBook Research · Company Intelligence

CONOCOPHILLIPS

COPNYSE

Built from CONOCOPHILLIPS's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

CONOCOPHILLIPS: Revenue grew 4.9% to $51.82B from $49.42B. Net income declined 13.6% to $7.988B from $9.245B. Operating cash flow declined 1.6% to $19.8B from $20.12B. Net margin contracted 330 bps to 15.41%. CONOCOPHILLIPS's annual comparison also shows stock compensation grew faster than revenue.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 4.9% to $51.82B from $49.42BOK
  • ProfitabilityNet income declined 13.6% to $7.988B from $9.245BWatch
  • Cash flowOperating cash flow declined 1.6% to $19.8B from $20.12BWatch
  • MarginsNet margin contracted 330 bps to 15.41%Watch
  • AccountingNo overriding statistical warningNote
  • Insiders1 purchase and 12 salesOK

Business

Surmont is a 100 percent working interest asset that offers sustained, long-life production.

Leadership changes

From CONOCOPHILLIPS's own filings, the day they're filed.

  • Nelda J. Connors · Directors · departure
  • Eric D. Mullins · member · departure

Latest filings

  • 8-K · Company announcement2026-08-11
  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-06-23
  • 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CONOCOPHILLIPS, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.